EBOS: Investment Complete, Growth Ahead
EBOS posts robust FY26 earnings, finishing investment cycle for future gains.
Key Points
Analysts at TipRanks rate EBOS as a Buy with a NZ$24.50 price target, signaling positive sentiment around the stock after FY26 results.
EBOS delivered FY26 revenue growth of 9.9% to about US$13.5 billion and underlying EBITDA up 5.0% to US$614 million despite fuel and foreign exchange headwinds.
TradingView notes the investment cycle has been completed, with Ebos positioned for productivity gains and a mid-single-digit EBITDA growth trajectory in FY27.
EBOS reported NPAT of A$250 million for the year, down from A$258 million in the prior year, reflecting ongoing cost pressures and prior guidance adjustments in April.
Analysts highlight CSO reforms as a tailwind supporting EBOS’s earnings growth, alongside continued expansion in health services, digital engagement, and owned pharmacy brands.
EBOS Group posted a strong FY26 result, with revenue climbing 9.9% to $13.5 billion and underlying EBITDA rising 5.0% to $614 million, according to Kalkine. The result caps a four-year, $360 million investment cycle that the company says is now complete.
The New Zealand-listed healthcare and animal care distributor declared a final dividend of NZD $0.615 per share. Management guided for mid-single-digit EBITDA growth in FY27, with capital spending set to normalise to around A$100 million — down sharply from recent elevated levels, Kalkine reported.
Healthcare and Animal Care Drive Broad Revenue Gains
Healthcare was the clear engine of growth. Revenue in that segment rose 8.5% to $12.6 billion, with EBITDA up 3.2% to $516 million, according to Kalkine. Demand for GLP-1 weight-loss drugs, record hospital sales, and an expanding TerryWhite Chemmart pharmacy network all contributed.
Animal care also performed well, adding to the company's diversified earnings base. EBOS acquired Paringa Pet Foods and K-Talyst during the period. Those deals expanded capacity and gave the company more control over its supply chain. Fuel and foreign exchange were headwinds, but did not derail overall growth.
NPAT Slips as Higher Costs Weigh on Bottom Line
Despite strong top-line growth, the bottom line told a different story. Underlying NPAT fell 3.1% to A$249.7 million, down from A$258 million a year earlier, Kalkine reported. Higher depreciation charges from the completed investment cycle were the main culprit.
Reported NPAT came in at $225.2 million for FY26. Earnings per share rose just 0.1%, and total dividends were maintained rather than increased. EBOS had flagged cost pressures in an April guidance update, so the result largely matched what the market expected, according to Kalkine.
Investment Cycle Done, Stronger Cash Flow Ahead
The completion of EBOS's $360 million distribution centre renewal is a key milestone. TipRanks noted the company is now positioned for productivity gains after years of heavy spending. Capital expenditure should fall to around A$100 million in FY27, which will free up significantly more cash.
TipRanks analysts rate EBOS as a Buy with a NZ$24.50 price target. CSO reforms — changes to how community service obligations in pharmacy are funded — are seen as a further tailwind. Expansion in health services, digital engagement, and owned pharmacy brands should support earnings from here.
FY27 Outlook: Mid-Single-Digit Growth and Less Spending
EBOS management reiterated guidance for mid-single-digit EBITDA growth in FY27. That target rests on three pillars: integrating recent acquisitions, growing the TerryWhite Chemmart network, and capturing the productivity gains from its new distribution centres, according to Kalkine.
The lower capex profile is the other big story for investors. With the heavy lifting done, EBOS can convert more earnings into cash and sustain its high dividend payout. The company said it plans to keep expanding its healthcare and retail pharmacy footprint as long-term demand trends remain strong, TipRanks reported.
Sentiment
Mostly PositivePublishers
10
Articles
0
Reach
10
